Anhui Huaren Health Pharmaceutical Co., Ltd. reports **CNY 4.31 billion in sales and revenue** for the nine months ended September 30, 2026. This marks an increase from **CNY 3.89 billion** in the same period of the prior year. The company’s financial results reflect growth in its pharmaceutical operations over the latest quarterly period.
Anhui Huaren Health Pharmaceutical Co., Ltd. reports **CNY 2.82 billion in revenue** and **CNY 2.77 billion in sales** for the first half of 2026. The figures mark year-over-year growth, with revenue up from CNY 2.50 billion and sales from CNY 2.45 billion in the same period of 2025. The company’s financial results reflect continued expansion in its pharmaceutical operations.
Anhui Huaren Health Pharmaceutical Co., Ltd. expects to raise **CNY 709.0743 million** through a private placement of **50 million A shares**, priced at no less than 80% of the 20-day average. The funds will be secured via a transaction approved by the company’s board, pending final regulatory clearance. Share transfer restrictions apply for **6 months** post-issuance.
Anhui Huaren Health Pharmaceutical Co., Ltd. declares an annual dividend of **CNY 0.10 per share**, payable to shareholders on **May 27, 2026**. The ex-date and record date are set for **May 27 and May 26, 2026**, respectively. This marks the company’s official dividend distribution schedule for the fiscal year.